China Sees Lobbying Tug-Of-War Over Drug Registration Regulation
This article was originally published in PharmAsia News
Executive Summary
Multinational and domestic drug companies are lobbying regulatory decision makers to amend China’s Drug Registration Regulation (DRR) from its present language. PharmAsia News provides an update on recent changes in the third draft of the DRR.